Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Original Article

R. Dummer, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, J.M. Kirkwood, V.C. Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, T. Lesimple, R. Plummer, K. Dasgupta, E. Gasal, M. Tan, G.V. Long, and D. Schadendorf

N Engl J Med 2020;383:1139-1148

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
09/16/2020
Course expires: 
09/17/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Saturday, September 17, 2022 - 11:59pm.